Skip to content

Enhancing Skeletal Adaptations to PTH and Exercise

Enhancing Skeletal Adaptation to Exercise by Attenuating the Acute Disruption of Calcium Homeostasis During Exercise

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05029128
Acronym
ESkAPE
Enrollment
18
Registered
2021-08-31
Start date
2023-01-01
Completion date
2025-12-01
Last updated
2026-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Formation, Bone Resorption, Exercise

Keywords

Acute exercise, Exercise training, Bone resorption, Bone formation, Parathyroid hormone, Calcium homeostasis

Brief summary

Exercise is essential for building and maintaining bone mass and strength, but current exercise recommendations for how to achieve this lack detail on the optimal exercise prescription. Recent studies found that blood calcium level decreases during exercise, and that calcium is mobilized from bone to slow the decline. If this occurs repeatedly during exercise training, it could diminish the potential benefits of exercise to improve bone health. The proposed study will determine whether further research on pre-exercise supplemental calcium to minimize the decline in blood calcium level during exercise is warranted. This research is important for Veterans because they are at increased risk of hip fracture when compared with non-Veterans. Further, because osteoporosis in men is under-recognized and under-treated, providing male (and female) Veterans with more specific exercise and nutrition guidelines has the potential to enhance bone health, reduce fracture risk, and improve quality of life.

Detailed description

Exercise is essential for building and maintaining bone mass and strength, but recent work has raised the possibility that current exercise recommendations for bone health may not be appropriate. There is strong evidence that a single bout of vigorous exercise has an acute catabolic effect in bone (i.e., increased resorption) that lasts several hours. This is mediated by a decrease in serum calcium (Ca) during exercise, which stimulates parathyroid hormone (PTH) secretion. PTH then activates bone resorption to mobilize Ca from bone, presumably to prevent the decrease in serum Ca from progressing to a harmful level. This cascade of events can be markedly attenuated by minimizing the decline in serum Ca during exercise via either intravenous or oral Ca administration. The timing of Ca supplementation relative to exercise is likely important, because it must be available for gut absorption during exercise. Interestingly, repeated pharmacologic stimulation of the PTH receptor with PTH analogs (teriparatide, abaloparatide) has anabolic effects on bone, suggesting that repeated exercise-induced increases in PTH could have a chronic anabolic skeletal effect, in addition to the acute catabolic effect, which may be apparent only after repeated exercise sessions. If this is the case, suppressing the PTH response with pre-exercise Ca supplementation may not be appropriate. In this context, this proof-of-concept study will include a short exercise intervention consisting of treadmill exercise at 70% to 80% of maximal heart rate, 60 minutes per day, 4 days per week, for 4 weeks. Serum markers of bone formation and resorption will be measured before, during, and for 24 hours after the 1st, 8th, and 16th exercise sessions to address two questions: 1) Does the acute catabolic response of bone to a single bout of exercise continue to occur with repeated exercise sessions (i.e., exercise training)? 2) Does exercise training also generate an anabolic PTH-mediated bone response, similar to the anabolic response to PTH analog therapy? If the answers to questions 1 and 2 are YES (persistent catabolic signal) and NO (lack of anabolic signal), this will support the need for the randomized controlled trial (RCT), which will evaluate whether taking Ca before exercise to attenuate the acute catabolic response improves skeletal adaptations to exercise training. The overarching goal is to improve the currently imprecise recommendations for exercise to improve and maintain bone health. This research is of high relevance to Veterans, who are at increased risk of hip fracture when compared with non-Veterans. Further, because osteoporosis in men is under-recognized, under-diagnosed, and under-treated, providing male Veterans with an effective non-pharmacologic therapeutic option to reduce fracture risk may help close this treatment gap. The potential impact of this research also extends beyond Veterans. It could lead to reduced risk of exercise-related bone injury (i.e., stress fractures) in active duty military personnel and athletes and to improved bone health in the general population.

Interventions

BEHAVIORALEndurance exercise intervention

All participants engage in treadmill walking 4 days/week, 60 minutes/day, at 70-80% of HRmax for 4 weeks.

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

All participants will undergo the same exercise intervention for this proof-of-concept project, so there is no randomization. The exercise will be treadmill walking at 70-80% of HRmax for 60 min/d, 4 d/wk, for 4 wk. The mode and intensity of exercise were selected because high-intensity weight-bearing exercise is recommended for bone health, and walking is the most common weight-bearing activity. Although "high-intensity" exercise for bone health refers to the intensity of bone-loading forces, %HRmax is a good proxy because peak bone-loading forces increase as walking or running speed increases. Exercise sessions will be supervised by the research team. This exercise prescription was used in the studies of young and older adults that provided the scientific premise for the current study and resulted in robust PTH and CTX responses.

Eligibility

Sex/Gender
ALL
Age
25 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Female and male Veterans aged 25 to 45 y and 55 to 75 y will be enrolled. Eligible volunteers will be normally active (e.g., recreational cycling or walking) but will not participate in regular moderate-to-vigorous exercise. Women will be premenopausal with regular menstrual cycles or postmenopausal, defined as absence of menses for at least 12 mo or, in those who underwent a hysterectomy, a serum follicle stimulating hormone (FSH) \>30 mIU/mL.

Exclusion criteria

* Initiation or change in dose in the past 6 months of medications that affect bone metabolism * e.g., osteoporosis medications, thiazide/loop diuretics, systemic glucocorticoids * BMD T-score \<-2.5 at the total hip, femoral neck, or lumbar spine * Impaired renal function, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2 * Abnormal alkaline phosphatase * Untreated thyroid dysfunction, defined as an ultrasensitive thyroid stimulating hormone (TSH) \<0.5 or \>5.0 mU/L * Serum Ca \<8.5 or \>10.3 mg/dL * Serum 25(OH)D \<20 ng/mL * Uncontrolled hypertension (resting systolic blood pressure (BP) \>150 mmHg or diastolic BP \>90 mmHg) * Type 1 diabetes * Type 2 diabetes if on insulin or sulfonylurea therapy * hemoglobin A1c \>7% * Cardiovascular disease; defined as subjective or objective indicators of ischemic heart disease (e.g., angina, ST segment depression) or serious arrhythmias at rest or during the graded exercise test (GXT) * volunteers who have a positive GXT can be re-considered after follow-up evaluation by a cardiologist * Anemia (hemoglobin \<12.1 g/dL for women, \<14.3 g/dL for men) * Fracture in the past 6 months * Body mass index \>39 kg/m2 * In the event of abnormal eGFR, alkaline phosphatase, TSH, BP, 25(OH)D, or hemoglobin values, volunteers can be reassessed, including after appropriate follow-up evaluation and treatment by their health care provider

Design outcomes

Primary

MeasureTime frameDescription
Change in C-terminal Peptide of Type 1 Collagen (CTX)The primary outcome for Aim 1 is the change in CTX from immediately before exercise to 60 minutes after exercise during the 1st, 8th, and 16th exercise bout. Results are for each exercise bout and for the average of all the bouts combined.CTX is a marker of bone resorption. An increase in CTX in response to exercise is evidence of an acute catabolic response of bone.
Change in Procollagen 1 Intact N-terminal Propeptide (P1NP)The primary outcome for Aim 2 is the change in the pre-exercise P1NP (15 minutes before exercise) between the 1st and the 16th exercise bout (comparison of 2 time points).P1NP is a marker of bone formation. An increase in P1NP from before to after an exercise intervention is evidence of an anabolic response of bone.

Secondary

MeasureTime frameDescription
Change in P1NP During ExerciseChange in serum P1NP is measured from before to immediately after the 60 minutes of exercise during the 1st, 8th, and 16th exercise bout. The average change across all exercise bouts is also included.Serum P1NP is measured to determine if there is an acute anabolic response of bone to exercise and whether it changes in response to exercise training
Urinary Calcium Excretion (uCa)Urinary Ca excretion is measured over the 4 hours of recovery after exercise. Results are presented for the 1st, 8th, and 16th exercise bout individually and for the average excretion across all 3 collections.Urinary tCa is used to account for Ca loss subsequent to the activation of bone resorption during exercise
Change in Serum Ionized Ca (iCa)Serum iCa is measured before and 15 minutes after the 60 minutes of exercise during the 1st, 8th, and 16th exercise bout. Average change across all three exercise collection bouts is also provided.Serum iCa is measured to assess the stimulus for PTH secretion and to describe the pattern of change in iCa during and after exercise
Change in Serum Total Ca (tCa)Change in serum tCa is measured before and 15 minutes after the 60 minute exercise bout during the 1st, 8th, and 16th exercise bouts. Average change across all 3 collection bouts is also included.Serum tCa is measured to help interpret changes in iCa (e.g., changes in Ca binding) and to describe the pattern of change in tCa during and after exercise
Change in Serum Parathyroid Hormone (PTH)Serum PTH is measured before and 15 minutes after the 60 minute exercise bout. Results are presented for the 1st, 8th, and 16th exercise bouts individually and for the average change across all 3 collection bouts.Serum PTH is measured to assess the stimulus for the activation of bone resorption and to describe the pattern of change in PTH during and after exercise
Change in Serum Phosphorus (PO4)Serum PO4 is measured before and 15 minutes after the end of the 60 minute exercise bout at the 1st, 8th, and 16th exercise bout. Overall change across all 3 visits is also reported.Serum PO4 is measured because it is a potential stimulus for PTH secretion
Change in Hematocrit (Hct)Hct is measured before and 15 minutes after the 60 minutes of exercise to correct for plasma volume shifts at the 1st, 8th, and 16th exercise bout. Average change across all 3 exercise bouts is also provided.Hct is used to adjust iCa, tCa, PTH, CTX, P1NP, and PO4 for the plasma volume contraction that occurs with exercise
Change in Hemoglobin (Hgb)Hgb is measured before and 15 minutes after 60 minutes of exercise to correct for plasma volume shifts. Results are presented for the 1st, 8th, and 16th exercise bouts individually and the average across all 3 exercise collection bouts.Hgb is used to adjust iCa, tCa, PTH, CTX, P1NP, and PO4 for the plasma volume contraction that occurs with exercise

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORWendy M Kohrt, PhD

Rocky Mountain Regional VA Medical Center, Aurora, CO

Participant flow

Recruitment details

Participants completed an initial in-person screening visit to assess whether inclusion/exclusion criteria were met. Participants were considered "enrolled" once the consent form was signed.

Pre-assignment details

Screening assessments occurred between consent/enrollment and the start of data collection. Of the 18 who signed the consent, 8 passed the screening assessments. All 8 participants who passed screening started the study and 6 completed the study. There is no randomization to a study arm so all participants completed the same exercise intervention (4 weeks of treadmill exercise).

Baseline characteristics

Characteristic
Age, Continuous54.2 Years
STANDARD_DEVIATION 21.4
Baseline CTX0.27 ng/mL
STANDARD_DEVIATION 0.16
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
7 Participants
Sex: Female, Male
Female
1 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 8
other
Total, other adverse events
2 / 8
serious
Total, serious adverse events
0 / 8

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026